Article Text
Statistics from Altmetric.com
Psoriatic arthritis (PsA) is a heterogeneous disease involving the musculoskeletal structures, the skin and nails.1 2 Traditional disease-modifying antirheumatic drugs and tumour necrosis factor β (TNFβ) antagonists are effective on cutaneous and articular manifestations of psoriatic disease.3 4
Most patients with PsA are successfully treated with TNFβ antagonists. However, a subset of patients with PsA are not responsive to these treatments or do not maintain a clinical response to the cutaneous manifestations despite the remission of arthritis.5
The primary objective of this study was to evaluate the safety and efficacy of adding ciclosporin A (CsA) to etanercept in patients with PsA demonstrating an unsatisfactory control of cutaneous …
Footnotes
-
Ethics approval This study was conducted with the approval of the Ospedale San Carlo.
-
Provenance and peer review Not commissioned; externally peer reviewed.